Research prototype, not medical advice.
Findings
What the data in the repository shows so far: published mouse lifespan results, which parts of the body our measure of biological age can already see, and the reproducible runs.
Mouse lifespan results (ITP)
The Interventions Testing Program feeds drugs to genetically mixed mice at three sites. Each dot is one group of treated mice (one drug, dose, start year and sex): how much longer, in percent, the middle mouse lived than in the untreated group. Green: the paper reports a lifespan gain. Grey: no clear effect. A hollow dot means some numbers in that file are still to be checked. Only the central value is shown: the files do not yet give uncertainty ranges, so no error bars are drawn. Click a dot to open its file.
108 of 132 groups have a median change; 74 of those still have numbers to check. Source: literature/lifespan/itp/ .
-10% -5% 0% +5% +10% +15% +20% +25% +30% +35% +40% 2017-1-3-butanediol-100000ppm-183d-f: +1.5% 1,3-butanediol females, 2017 cohort, 100000 ppm +1.5% 2017-1-3-butanediol-100000ppm-183d-m: +9.3% males, 2017 cohort, 100000 ppm +9.3% 2015-17-dmag-30ppm-183d-f: -4.3% (to check) 17-DMAG females, 2015 cohort, 30 ppm -4.3% (to check) 2015-17-dmag-30ppm-183d-m: +9.3% (to check) males, 2015 cohort, 30 ppm +9.3% (to check) 2009-17-alpha-estradiol-4.8ppm-304d-f: -0.3% (to check) 17-alpha-estradiol females, 2009 cohort, 4.8 ppm -0.3% (to check) 2009-17-alpha-estradiol-4.8ppm-304d-m: +11.5% (to check) males, 2009 cohort, 4.8 ppm +11.5% (to check) 2011-17-alpha-estradiol-14.4ppm-304d-f: +1.0% (to check) females, 2011 cohort, 14.4 ppm +1.0% (to check) 2011-17-alpha-estradiol-14.4ppm-304d-m: +18.6% (to check) males, 2011 cohort, 14.4 ppm +18.6% (to check) 2016-17-alpha-estradiol-14.4ppm-487d-m: +18.6% males, 2016 cohort, 14.4 ppm +18.6% 2016-17-alpha-estradiol-14.4ppm-609d-m: +10.7% males, 2016 cohort, 14.4 ppm +10.7% 2012-hbx-1ppm-457d-f: -2.4% (to check) 2-(2-hydroxyphenyl)benzothiazole females, 2012 cohort, 1 ppm -2.4% (to check) 2012-hbx-1ppm-457d-m: +0.7% (to check) males, 2012 cohort, 1 ppm +0.7% (to check) 2016-mif098-240ppm-244d-f: -1.3% MIF098 females, 2016 cohort, 240 ppm -1.3% 2016-mif098-240ppm-244d-m: +4.3% males, 2016 cohort, 240 ppm +4.3% 2015-mitoq-100ppm-213d-f: -1.7% (to check) MitoQ females, 2015 cohort, 100 ppm -1.7% (to check) 2015-mitoq-100ppm-213d-m: +1.6% (to check) males, 2015 cohort, 100 ppm +1.6% (to check) 2014-tm5441-60ppm-335d-f: -0.3% (to check) TM5441 females, 2014 cohort, 60 ppm -0.3% (to check) 2014-tm5441-60ppm-335d-m: -3.6% (to check) males, 2014 cohort, 60 ppm -3.6% (to check) 2009-acarbose-1000ppm-122d-f: +4.8% (to check) acarbose females, 2009 cohort, 1000 ppm +4.8% (to check) 2009-acarbose-1000ppm-122d-m: +21.9% (to check) males, 2009 cohort, 1000 ppm +21.9% (to check) 2012-acarbose-1000ppm-487d-f: +2.4% (to check) females, 2012 cohort, 1000 ppm +2.4% (to check) 2012-acarbose-1000ppm-487d-m: +6.3% (to check) males, 2012 cohort, 1000 ppm +6.3% (to check) 2013-acarbose-1000ppm-244d-f: +4.9% females, 2013 cohort, 1000 ppm +4.9% 2013-acarbose-2500ppm-244d-f: +3.7% females, 2013 cohort, 2500 ppm +3.7% 2013-acarbose-400ppm-244d-f: -0.2% females, 2013 cohort, 400 ppm -0.2% 2013-acarbose-1000ppm-244d-m: +17.5% males, 2013 cohort, 1000 ppm +17.5% 2013-acarbose-2500ppm-244d-m: +16.1% males, 2013 cohort, 2500 ppm +16.1% 2013-acarbose-400ppm-244d-m: +10.6% males, 2013 cohort, 400 ppm +10.6% 2004-aspirin-21ppm-122d-m: +8.0% (to check) aspirin males, 2004 cohort, 21 ppm +8.0% (to check) 2014-aspirin-200ppm-335d-f: +1.0% (to check) females, 2014 cohort, 200 ppm +1.0% (to check) 2014-aspirin-60ppm-335d-f: +1.2% (to check) females, 2014 cohort, 60 ppm +1.2% (to check) 2014-aspirin-200ppm-335d-m: +0.6% (to check) males, 2014 cohort, 200 ppm +0.6% (to check) 2014-aspirin-60ppm-335d-m: -1.4% (to check) males, 2014 cohort, 60 ppm -1.4% (to check) 2015-beta-gpa-3300ppm-183d-f: -1.3% (to check) beta-guanidinopropionic acid females, 2015 cohort, 3300 ppm -1.3% (to check) 2015-beta-gpa-3300ppm-183d-m: -1.0% (to check) males, 2015 cohort, 3300 ppm -1.0% (to check) 2016-canagliflozin-180ppm-213d-f: +1.4% (to check) canagliflozin females, 2016 cohort, 180 ppm +1.4% (to check) 2016-canagliflozin-180ppm-213d-m: +14.0% (to check) males, 2016 cohort, 180 ppm +14.0% (to check) 2016-candesartan-cilexetil-30ppm-244d-f: +0.7% candesartan cilexetil females, 2016 cohort, 30 ppm +0.7% 2016-candesartan-cilexetil-30ppm-244d-m: +4.2% males, 2016 cohort, 30 ppm +4.2% 2017-captopril-180ppm-152d-f: +5.4% captopril females, 2017 cohort, 180 ppm +5.4% 2017-captopril-180ppm-152d-m: +14.3% males, 2017 cohort, 180 ppm +14.3% 2007-curcumin-2000ppm-122d-f: +4.5% (to check) curcumin females, 2007 cohort, 2000 ppm +4.5% (to check) 2007-curcumin-2000ppm-122d-m: +2.8% (to check) males, 2007 cohort, 2000 ppm +2.8% (to check) 2010-fish-oil-15000ppm-274d-f: -5.3% (to check) fish oil females, 2010 cohort, 15000 ppm -5.3% (to check) 2010-fish-oil-50000ppm-274d-f: +2.1% (to check) females, 2010 cohort, 50000 ppm +2.1% (to check) 2010-fish-oil-15000ppm-274d-m: +6.4% (to check) males, 2010 cohort, 15000 ppm +6.4% (to check) 2010-fish-oil-50000ppm-274d-m: -4.0% (to check) males, 2010 cohort, 50000 ppm -4.0% (to check) 2016-geranylgeranylacetone-600ppm-274d-f: +2.3% geranylgeranylacetone females, 2016 cohort, 600 ppm +2.3% 2016-geranylgeranylacetone-600ppm-274d-m: +4.8% males, 2016 cohort, 600 ppm +4.8% 2014-glycine-80000ppm-274d-f: +3.6% glycine females, 2014 cohort, 80000 ppm +3.6% 2014-glycine-80000ppm-274d-m: +6.3% males, 2014 cohort, 80000 ppm +6.3% 2007-green-tea-extract-2000ppm-122d-f: +6.6% (to check) green tea extract females, 2007 cohort, 2000 ppm +6.6% (to check) 2007-green-tea-extract-2000ppm-122d-m: +4.6% (to check) males, 2007 cohort, 2000 ppm +4.6% (to check) 2012-int-767-180ppm-304d-f: -1.0% (to check) int-767 females, 2012 cohort, 180 ppm -1.0% (to check) 2012-int-767-180ppm-304d-m: -3.1% (to check) males, 2012 cohort, 180 ppm -3.1% (to check) 2014-inulin-600ppm-335d-f: +1.4% (to check) inulin females, 2014 cohort, 600 ppm +1.4% (to check) 2014-inulin-600ppm-335d-m: -2.0% (to check) males, 2014 cohort, 600 ppm -2.0% (to check) 2017-leucine-40000ppm-152d-f: -1.7% leucine females, 2017 cohort, 40000 ppm -1.7% 2017-leucine-40000ppm-152d-m: +0.3% males, 2017 cohort, 40000 ppm +0.3% 2007-mct-oil-60000ppm-122d-f: +1.8% (to check) medium-chain triglyceride oil females, 2007 cohort, 60000 ppm +1.8% (to check) 2007-mct-oil-60000ppm-122d-m: -1.1% (to check) males, 2007 cohort, 60000 ppm -1.1% (to check) 2011-metformin-1000ppm-274d-f: -0.2% (to check) metformin females, 2011 cohort, 1000 ppm -0.2% (to check) 2011-metformin-1000ppm-274d-m: +7.1% (to check) males, 2011 cohort, 1000 ppm +7.1% (to check) 2011-metformin-rapamycin-1000-14ppm-274d-f: +23.3% (to check) metformin + rapamycin females, 2011 cohort, 1000+14 ppm +23.3% (to check) 2011-metformin-rapamycin-1000-14ppm-274d-m: +22.9% (to check) males, 2011 cohort, 1000+14 ppm +22.9% (to check) 2009-methylene-blue-28ppm-122d-f: +0.7% (to check) methylene blue females, 2009 cohort, 28 ppm +0.7% (to check) 2009-methylene-blue-28ppm-122d-m: -2.1% (to check) males, 2009 cohort, 28 ppm -2.1% (to check) 2015-minocycline-300ppm-183d-f: -3.0% (to check) minocycline females, 2015 cohort, 300 ppm -3.0% (to check) 2015-minocycline-300ppm-183d-m: +4.5% (to check) males, 2015 cohort, 300 ppm +4.5% (to check) 2004-ndga-2500ppm-274d-m: +12.1% (to check) ndga males, 2004 cohort, 2500 ppm +12.1% (to check) 2010-ndga-5000ppm-183d-f: -2.9% (to check) females, 2010 cohort, 5000 ppm -2.9% (to check) 2010-ndga-2500ppm-183d-m: +9.1% (to check) males, 2010 cohort, 2500 ppm +9.1% (to check) 2010-ndga-5000ppm-183d-m: +7.6% (to check) males, 2010 cohort, 5000 ppm +7.6% (to check) 2010-ndga-800ppm-183d-m: +6.5% (to check) males, 2010 cohort, 800 ppm +6.5% (to check) 2016-nicotinamide-riboside-1000ppm-244d-f: +0.1% nicotinamide riboside females, 2016 cohort, 1000 ppm +0.1% 2016-nicotinamide-riboside-1000ppm-244d-m: -3.0% males, 2016 cohort, 1000 ppm -3.0% 2007-oxaloacetic-acid-2200ppm-122d-f: +2.7% (to check) oxaloacetic acid females, 2007 cohort, 2200 ppm +2.7% (to check) 2007-oxaloacetic-acid-2200ppm-122d-m: +4.2% (to check) males, 2007 cohort, 2200 ppm +4.2% (to check) 2017-pb125-4.7+9+0.47ppm-152d-f: +0.8% pb125 females, 2017 cohort, 4.7+9+0.47 ppm +0.8% 2017-pb125-4.7+9+0.47ppm-152d-m: -2.6% males, 2017 cohort, 4.7+9+0.47 ppm -2.6% 2011-protandim-600ppm-304d-f: +2.5% (to check) protandim females, 2011 cohort, 600 ppm +2.5% (to check) 2011-protandim-600ppm-304d-m: +6.9% (to check) males, 2011 cohort, 600 ppm +6.9% (to check) 2009-rapamycin-14ppm-274d-f: +21.2% (to check) rapamycin females, 2009 cohort, 14 ppm +21.2% (to check) 2009-rapamycin-4.7ppm-274d-f: +16.4% (to check) females, 2009 cohort, 4.7 ppm +16.4% (to check) 2009-rapamycin-42ppm-274d-f: +26.3% (to check) females, 2009 cohort, 42 ppm +26.3% (to check) 2009-rapamycin-14ppm-274d-m: +12.6% (to check) males, 2009 cohort, 14 ppm +12.6% (to check) 2009-rapamycin-4.7ppm-274d-m: +3.3% (to check) males, 2009 cohort, 4.7 ppm +3.3% (to check) 2009-rapamycin-42ppm-274d-m: +22.9% (to check) males, 2009 cohort, 42 ppm +22.9% (to check) 2015-rapamycin-42ppm-604d-cycles-f: +8.0% (to check) females, 2015 cohort, 42 ppm +8.0% (to check) 2015-rapamycin-42ppm-604d-f: +14.9% (to check) females, 2015 cohort, 42 ppm +14.9% (to check) 2015-rapamycin-42ppm-604d-stop23mo-f: +3.9% (to check) females, 2015 cohort, 42 ppm +3.9% (to check) 2015-rapamycin-42ppm-604d-cycles-m: +8.9% (to check) males, 2015 cohort, 42 ppm +8.9% (to check) 2015-rapamycin-42ppm-604d-m: +10.9% (to check) males, 2015 cohort, 42 ppm +10.9% (to check) 2015-rapamycin-42ppm-604d-stop23mo-m: +10.6% (to check) males, 2015 cohort, 42 ppm +10.6% (to check) 2017-rapamycin-acarbose-14.7+1000ppm-274d-f: +27.5% rapamycin + acarbose females, 2017 cohort, 14.7+1000 ppm +27.5% 2017-rapamycin-acarbose-14.7+1000ppm-487d-f: +12.4% females, 2017 cohort, 14.7+1000 ppm +12.4% 2017-rapamycin-acarbose-14.7+1000ppm-274d-m: +36.6% males, 2017 cohort, 14.7+1000 ppm +36.6% 2017-rapamycin-acarbose-14.7+1000ppm-487d-m: +13.5% males, 2017 cohort, 14.7+1000 ppm +13.5% 2007-resveratrol-300ppm-122d-f: +4.7% (to check) resveratrol females, 2007 cohort, 300 ppm +4.7% (to check) 2007-resveratrol-300ppm-122d-m: +3.4% (to check) males, 2007 cohort, 300 ppm +3.4% (to check) 2017-sulindac-5ppm-152d-f: -1.7% sulindac females, 2017 cohort, 5 ppm -1.7% 2017-sulindac-5ppm-152d-m: -2.8% males, 2017 cohort, 5 ppm -2.8% 2017-syringaresinol-300ppm-152d-f: -1.7% syringaresinol females, 2017 cohort, 300 ppm -1.7% 2017-syringaresinol-300ppm-152d-m: +6.3% males, 2017 cohort, 300 ppm +6.3% 2011-udca-5000ppm-152d-f: -1.0% (to check) ursodeoxycholic acid females, 2011 cohort, 5000 ppm -1.0% (to check) 2011-udca-5000ppm-152d-m: +6.7% (to check) males, 2011 cohort, 5000 ppm +6.7% (to check) 2013-ursolic-acid-2000ppm-304d-f: -0.4% (to check) ursolic acid females, 2013 cohort, 2000 ppm -0.4% (to check) 2013-ursolic-acid-2000ppm-304d-m: +6.4% (to check) males, 2013 cohort, 2000 ppm +6.4% (to check)
24 group(s) with no median change in the file yet
4-oh-pbn , females, 2004 cohort, 350 ppm4-oh-pbn , males, 2004 cohort, 350 ppmaspirin , females, 2004 cohort, 21 ppmcape , females, 2005 cohort, 300 ppmcape , females, 2005 cohort, 30 ppmcape , males, 2005 cohort, 300 ppmcape , males, 2005 cohort, 30 ppmenalapril , females, 2005 cohort, 120 ppmenalapril , males, 2005 cohort, 120 ppmndga , females, 2004 cohort, 2500 ppmnfp , females, 2004 cohort, 200 ppmnfp , males, 2004 cohort, 200 ppmrapamycin , females, 2005 cohort, 14 ppmrapamycin , males, 2005 cohort, 14 ppmrapamycin , females, 2006 cohort, 14 ppmrapamycin , males, 2006 cohort, 14 ppmresveratrol , females, 2006 cohort, 1200 ppmresveratrol , females, 2006 cohort, 300 ppmresveratrol , males, 2006 cohort, 1200 ppmresveratrol , males, 2006 cohort, 300 ppmsimvastatin , females, 2006 cohort, 120 ppmsimvastatin , females, 2006 cohort, 12 ppmsimvastatin , males, 2006 cohort, 120 ppmsimvastatin , males, 2006 cohort, 12 ppm
Coverage of the biological-age measure
Biological age is measured on many axes: one per organ system and one per hallmark of ageing. An axis with no public data to read it from is a blind spot; it stays on the list until one is found. Source: research/metric/v0/axes.md (draft).
35 axes: 12 with a public readout 13 with molecular data only 10 blind spots
Organ systems
A1 Skeletal muscle molecular data only A2 Bone blind spot: no public readout yet A3 Brain, cognition molecular data only A4 Hearing blind spot: no public readout yet A5 Vision blind spot: no public readout yet A6 Heart molecular data only A7 Vessels blind spot: no public readout yet A8 Lung molecular data only A9 Kidney molecular data only A10 Liver and metabolism public readout named A11 Immune system molecular data only A12 Blood molecular data only A13 Skin and hair public readout named A14 Gut molecular data only A15 Fat tissue public readout named A16 Endocrine and reproduction blind spot: no public readout yet A17 Neoplasia blind spot: no public readout yet A18 Whole-body frailty public readout named A8 lung function public readout named A9 GFR / albuminuria public readout named A12 complete blood count public readout named A15 fat mass (trajectory) public readout named
Hallmarks of ageing
H1 Genomic instability blind spot: no public readout yet H2 Telomere attrition blind spot: no public readout yet H3 Epigenetic alterations public readout named H4 Loss of proteostasis molecular data only H5 Disabled macroautophagy blind spot: no public readout yet H6 Deregulated nutrient sensing public readout named H7 Mitochondrial dysfunction molecular data only H8 Cellular senescence public readout named H9 Stem cell exhaustion molecular data only H10 Altered intercellular communication blind spot: no public readout yet H11 Chronic inflammation molecular data only H12 Dysbiosis molecular data only H11 plasma IL-6 / TNF public readout named
Simulation challenge (R-Sim v0)
Our simulation models each organ as a balance: damage is made at some rate and repaired at some rate. Measuring old mice only shows the balance, not the two rates, so we cannot tell "makes a lot of damage, repairs a lot" from "makes little, repairs little". A challenge is a deliberate, controlled injury (for example a drug that briefly harms the kidney), followed by measurements over the next 26 weeks: how fast the organ recovers tells the two rates apart. These results are from the simulation only; no mouse has been used.
Which challenges tell damage made apart from damage repaired
Each cell is one simulated experiment with 100 mice per measurement time: one organ, injured at 6 or 18 months of age, with a small, medium or large injury (0.15, 0.3 or 0.6 of the damage level the organ can stand). The number, from 0 to 1, says how well that experiment separates damage made from damage repaired. Dark cells, 0.8 and above, count as split : the two rates can be told apart. The three panels assume three values of kappa, how quickly repair hits its limit as damage builds up: 0.5 is our current guess, 2 and 8 mean repair stays far from its limit. Splitting happens only for injuries at 6 months with the medium or large dose, and nowhere when kappa is 8. Click a cell to open the file.
Muscle Brain Heart Lung Kidney Liver and metabolism Immune system Blood Skin and hair Gut Fat Repair limit kappa 0.5 (current guess) injured at 6 months 0.15 0.3 0.6 injured at 18 months 0.15 0.3 0.6 Muscle, injured at 6 months, injury 0.15: 0.22 0.22 Muscle, injured at 6 months, injury 0.3: 0.92 0.92 Muscle, injured at 6 months, injury 0.6: 0.98 0.98 Muscle, injured at 18 months, injury 0.15: 0.19 0.19 Muscle, injured at 18 months, injury 0.3: 0.16 0.16 Muscle, injured at 18 months, injury 0.6: 0.14 0.14 Brain, injured at 6 months, injury 0.15: 0.19 0.19 Brain, injured at 6 months, injury 0.3: 0.20 0.20 Brain, injured at 6 months, injury 0.6: 0.98 0.98 Brain, injured at 18 months, injury 0.15: 0.20 0.20 Brain, injured at 18 months, injury 0.3: 0.16 0.16 Brain, injured at 18 months, injury 0.6: 0.06 0.06 Heart, injured at 6 months, injury 0.15: 0.20 0.20 Heart, injured at 6 months, injury 0.3: 0.20 0.20 Heart, injured at 6 months, injury 0.6: 0.97 0.97 Heart, injured at 18 months, injury 0.15: 0.19 0.19 Heart, injured at 18 months, injury 0.3: 0.14 0.14 Heart, injured at 18 months, injury 0.6: 0.06 0.06 Lung, injured at 6 months, injury 0.15: 0.19 0.19 Lung, injured at 6 months, injury 0.3: 0.95 0.95 Lung, injured at 6 months, injury 0.6: 0.97 0.97 Lung, injured at 18 months, injury 0.15: 0.20 0.20 Lung, injured at 18 months, injury 0.3: 0.16 0.16 Lung, injured at 18 months, injury 0.6: 0.06 0.06 Kidney, injured at 6 months, injury 0.15: 0.22 0.22 Kidney, injured at 6 months, injury 0.3: 0.20 0.20 Kidney, injured at 6 months, injury 0.6: 0.96 0.96 Kidney, injured at 18 months, injury 0.15: 0.21 0.21 Kidney, injured at 18 months, injury 0.3: 0.16 0.16 Kidney, injured at 18 months, injury 0.6: 0.06 0.06 Liver and metabolism, injured at 6 months, injury 0.15: 0.19 0.19 Liver and metabolism, injured at 6 months, injury 0.3: 0.96 0.96 Liver and metabolism, injured at 6 months, injury 0.6: 0.96 0.96 Liver and metabolism, injured at 18 months, injury 0.15: 0.21 0.21 Liver and metabolism, injured at 18 months, injury 0.3: 0.15 0.15 Liver and metabolism, injured at 18 months, injury 0.6: 0.08 0.08 Immune system, injured at 6 months, injury 0.15: 0.20 0.20 Immune system, injured at 6 months, injury 0.3: 0.21 0.21 Immune system, injured at 6 months, injury 0.6: 0.96 0.96 Immune system, injured at 18 months, injury 0.15: 0.21 0.21 Immune system, injured at 18 months, injury 0.3: 0.16 0.16 Immune system, injured at 18 months, injury 0.6: 0.07 0.07 Blood, injured at 6 months, injury 0.15: 0.21 0.21 Blood, injured at 6 months, injury 0.3: 0.93 0.93 Blood, injured at 6 months, injury 0.6: 0.97 0.97 Blood, injured at 18 months, injury 0.15: 0.22 0.22 Blood, injured at 18 months, injury 0.3: 0.15 0.15 Blood, injured at 18 months, injury 0.6: 0.06 0.06 Skin and hair, injured at 6 months, injury 0.15: 0.23 0.23 Skin and hair, injured at 6 months, injury 0.3: 0.88 0.88 Skin and hair, injured at 6 months, injury 0.6: 0.96 0.96 Skin and hair, injured at 18 months, injury 0.15: 0.19 0.19 Skin and hair, injured at 18 months, injury 0.3: 0.16 0.16 Skin and hair, injured at 18 months, injury 0.6: 0.14 0.14 Gut, injured at 6 months, injury 0.15: 0.24 0.24 Gut, injured at 6 months, injury 0.3: 0.90 0.90 Gut, injured at 6 months, injury 0.6: 0.97 0.97 Gut, injured at 18 months, injury 0.15: 0.19 0.19 Gut, injured at 18 months, injury 0.3: 0.16 0.16 Gut, injured at 18 months, injury 0.6: 0.13 0.13 Fat, injured at 6 months, injury 0.15: 0.24 0.24 Fat, injured at 6 months, injury 0.3: 0.89 0.89 Fat, injured at 6 months, injury 0.6: 0.96 0.96 Fat, injured at 18 months, injury 0.15: 0.18 0.18 Fat, injured at 18 months, injury 0.3: 0.15 0.15 Fat, injured at 18 months, injury 0.6: 0.13 0.13 Repair limit kappa 2 injured at 6 months 0.15 0.3 0.6 injured at 18 months 0.15 0.3 0.6 Muscle, injured at 6 months, injury 0.15: 0.20 0.20 Muscle, injured at 6 months, injury 0.3: 0.19 0.19 Muscle, injured at 6 months, injury 0.6: 0.88 0.88 Muscle, injured at 18 months, injury 0.15: 0.24 0.24 Muscle, injured at 18 months, injury 0.3: 0.22 0.22 Muscle, injured at 18 months, injury 0.6: 0.20 0.20 Brain, injured at 6 months, injury 0.15: 0.23 0.23 Brain, injured at 6 months, injury 0.3: 0.22 0.22 Brain, injured at 6 months, injury 0.6: 0.98 0.98 Brain, injured at 18 months, injury 0.15: 0.25 0.25 Brain, injured at 18 months, injury 0.3: 0.19 0.19 Brain, injured at 18 months, injury 0.6: 0.17 0.17 Heart, injured at 6 months, injury 0.15: 0.22 0.22 Heart, injured at 6 months, injury 0.3: 0.19 0.19 Heart, injured at 6 months, injury 0.6: 0.15 0.15 Heart, injured at 18 months, injury 0.15: 0.22 0.22 Heart, injured at 18 months, injury 0.3: 0.20 0.20 Heart, injured at 18 months, injury 0.6: 0.17 0.17 Lung, injured at 6 months, injury 0.15: 0.21 0.21 Lung, injured at 6 months, injury 0.3: 0.20 0.20 Lung, injured at 6 months, injury 0.6: 0.89 0.89 Lung, injured at 18 months, injury 0.15: 0.24 0.24 Lung, injured at 18 months, injury 0.3: 0.21 0.21 Lung, injured at 18 months, injury 0.6: 0.14 0.14 Kidney, injured at 6 months, injury 0.15: 0.21 0.21 Kidney, injured at 6 months, injury 0.3: 0.19 0.19 Kidney, injured at 6 months, injury 0.6: 0.79 0.79 Kidney, injured at 18 months, injury 0.15: 0.24 0.24 Kidney, injured at 18 months, injury 0.3: 0.21 0.21 Kidney, injured at 18 months, injury 0.6: 0.15 0.15 Liver and metabolism, injured at 6 months, injury 0.15: 0.20 0.20 Liver and metabolism, injured at 6 months, injury 0.3: 0.18 0.18 Liver and metabolism, injured at 6 months, injury 0.6: 0.92 0.92 Liver and metabolism, injured at 18 months, injury 0.15: 0.22 0.22 Liver and metabolism, injured at 18 months, injury 0.3: 0.19 0.19 Liver and metabolism, injured at 18 months, injury 0.6: 0.17 0.17 Immune system, injured at 6 months, injury 0.15: 0.23 0.23 Immune system, injured at 6 months, injury 0.3: 0.24 0.24 Immune system, injured at 6 months, injury 0.6: 0.93 0.93 Immune system, injured at 18 months, injury 0.15: 0.25 0.25 Immune system, injured at 18 months, injury 0.3: 0.20 0.20 Immune system, injured at 18 months, injury 0.6: 0.15 0.15 Blood, injured at 6 months, injury 0.15: 0.22 0.22 Blood, injured at 6 months, injury 0.3: 0.18 0.18 Blood, injured at 6 months, injury 0.6: 0.12 0.12 Blood, injured at 18 months, injury 0.15: 0.22 0.22 Blood, injured at 18 months, injury 0.3: 0.19 0.19 Blood, injured at 18 months, injury 0.6: 0.13 0.13 Skin and hair, injured at 6 months, injury 0.15: 0.20 0.20 Skin and hair, injured at 6 months, injury 0.3: 0.19 0.19 Skin and hair, injured at 6 months, injury 0.6: 0.17 0.17 Skin and hair, injured at 18 months, injury 0.15: 0.23 0.23 Skin and hair, injured at 18 months, injury 0.3: 0.22 0.22 Skin and hair, injured at 18 months, injury 0.6: 0.20 0.20 Gut, injured at 6 months, injury 0.15: 0.20 0.20 Gut, injured at 6 months, injury 0.3: 0.19 0.19 Gut, injured at 6 months, injury 0.6: 0.18 0.18 Gut, injured at 18 months, injury 0.15: 0.23 0.23 Gut, injured at 18 months, injury 0.3: 0.22 0.22 Gut, injured at 18 months, injury 0.6: 0.20 0.20 Fat, injured at 6 months, injury 0.15: 0.21 0.21 Fat, injured at 6 months, injury 0.3: 0.20 0.20 Fat, injured at 6 months, injury 0.6: 0.19 0.19 Fat, injured at 18 months, injury 0.15: 0.23 0.23 Fat, injured at 18 months, injury 0.3: 0.21 0.21 Fat, injured at 18 months, injury 0.6: 0.19 0.19 Repair limit kappa 8 injured at 6 months 0.15 0.3 0.6 injured at 18 months 0.15 0.3 0.6 Muscle, injured at 6 months, injury 0.15: 0.19 0.19 Muscle, injured at 6 months, injury 0.3: 0.19 0.19 Muscle, injured at 6 months, injury 0.6: 0.18 0.18 Muscle, injured at 18 months, injury 0.15: 0.23 0.23 Muscle, injured at 18 months, injury 0.3: 0.23 0.23 Muscle, injured at 18 months, injury 0.6: 0.22 0.22 Brain, injured at 6 months, injury 0.15: 0.05 0.05 Brain, injured at 6 months, injury 0.3: 0.04 0.04 Brain, injured at 6 months, injury 0.6: 0.00 0.00 Brain, injured at 18 months, injury 0.15: 0.04 0.04 Brain, injured at 18 months, injury 0.3: 0.02 0.02 Brain, injured at 18 months, injury 0.6: 0.01 0.01 Heart, injured at 6 months, injury 0.15: 0.12 0.12 Heart, injured at 6 months, injury 0.3: 0.13 0.13 Heart, injured at 6 months, injury 0.6: 0.15 0.15 Heart, injured at 18 months, injury 0.15: 0.18 0.18 Heart, injured at 18 months, injury 0.3: 0.17 0.17 Heart, injured at 18 months, injury 0.6: 0.17 0.17 Lung, injured at 6 months, injury 0.15: 0.00 0.00 Lung, injured at 6 months, injury 0.3: 0.00 0.00 Lung, injured at 6 months, injury 0.6: 0.00 0.00 Lung, injured at 18 months, injury 0.15: 0.02 0.02 Lung, injured at 18 months, injury 0.3: 0.01 0.01 Lung, injured at 18 months, injury 0.6: 0.00 0.00 Kidney, injured at 6 months, injury 0.15: 0.00 0.00 Kidney, injured at 6 months, injury 0.3: 0.00 0.00 Kidney, injured at 6 months, injury 0.6: 0.01 0.01 Kidney, injured at 18 months, injury 0.15: 0.07 0.07 Kidney, injured at 18 months, injury 0.3: 0.03 0.03 Kidney, injured at 18 months, injury 0.6: 0.00 0.00 Liver and metabolism, injured at 6 months, injury 0.15: 0.40 0.40 Liver and metabolism, injured at 6 months, injury 0.3: 0.41 0.41 Liver and metabolism, injured at 6 months, injury 0.6: 0.41 0.41 Liver and metabolism, injured at 18 months, injury 0.15: 0.44 0.44 Liver and metabolism, injured at 18 months, injury 0.3: 0.43 0.43 Liver and metabolism, injured at 18 months, injury 0.6: 0.39 0.39 Immune system, injured at 6 months, injury 0.15: 0.03 0.03 Immune system, injured at 6 months, injury 0.3: 0.03 0.03 Immune system, injured at 6 months, injury 0.6: 0.13 0.13 Immune system, injured at 18 months, injury 0.15: 0.04 0.04 Immune system, injured at 18 months, injury 0.3: 0.23 0.23 Immune system, injured at 18 months, injury 0.6: 0.15 0.15 Blood, injured at 6 months, injury 0.15: 0.11 0.11 Blood, injured at 6 months, injury 0.3: 0.10 0.10 Blood, injured at 6 months, injury 0.6: 0.39 0.39 Blood, injured at 18 months, injury 0.15: 0.41 0.41 Blood, injured at 18 months, injury 0.3: 0.41 0.41 Blood, injured at 18 months, injury 0.6: 0.36 0.36 Skin and hair, injured at 6 months, injury 0.15: 0.36 0.36 Skin and hair, injured at 6 months, injury 0.3: 0.36 0.36 Skin and hair, injured at 6 months, injury 0.6: 0.37 0.37 Skin and hair, injured at 18 months, injury 0.15: 0.23 0.23 Skin and hair, injured at 18 months, injury 0.3: 0.23 0.23 Skin and hair, injured at 18 months, injury 0.6: 0.22 0.22 Gut, injured at 6 months, injury 0.15: 0.21 0.21 Gut, injured at 6 months, injury 0.3: 0.21 0.21 Gut, injured at 6 months, injury 0.6: 0.21 0.21 Gut, injured at 18 months, injury 0.15: 0.24 0.24 Gut, injured at 18 months, injury 0.3: 0.23 0.23 Gut, injured at 18 months, injury 0.6: 0.23 0.23 Fat, injured at 6 months, injury 0.15: 0.00 0.00 Fat, injured at 6 months, injury 0.3: 0.00 0.00 Fat, injured at 6 months, injury 0.6: 0.00 0.00 Fat, injured at 18 months, injury 0.15: 0.21 0.21 Fat, injured at 18 months, injury 0.3: 0.20 0.20 Fat, injured at 18 months, injury 0.6: 0.20 0.20
below 0.2 0.2 to 0.5 0.5 to 0.8 0.8 and above: split
Source: result-20000.json (20 000 simulated mice per setting, GitHub Actions run 39594585409).
How many mice an experiment would need
The same results, read as a budget: for a given number of mice per sex, the most organs that any challenge design of that size or smaller can split. A design picks the age(s) at injury, the dose(s), and the number of mice per measurement time. Solid lines count all organs; dashed lines count only organs whose measurement can be repeated on the same mice (heart scan, kidney filtration, blood count, gut), the cheapest kind of experiment. At our current guess for kappa, about 200 mice per sex split the four repeatable organs; 300 per sex (two doses) still works if kappa is 2. If kappa is 8, no design up to 700 mice splits anything: kappa must be pinned down first. Click the chart to open the file.
Source: cost-curve.json . Method and full table: identifiability.md (section 11). Public data that could stand in for mice: public-data.md .
Reproducible runs
Each run is re-run on every change and must give the same output files, byte for byte. Source: research/runs/ .